ERBB2 and neoplasm: Further research published in nature indicated that during the treatment of HER2/CD3/C28 tri‐specific antibody targeting HER2 and T cells, CD4+T cells can not only promote the activity of CD8+ T cells but inhibit the division of tumor cells in a cell‐dependent manner.